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1. Executive Summary 
  For this project, we aimed to model an implantable poly (lactic-co-glycolic) (PLG) scaffold for 
the co-delivery of vascular endothelial growth factor (VEGF) and its antibody, anti-VEGF. The goal of 
this device is to deliver a therapeutic amount of VEGF to a desirable targeted tissue area to promote 
angiogenesis  with  high  spatial  and  temporal  resolution.  Using  COMSOL  software,  we  modeled  the 
interstitial implantation of PLG scaffold, containing a layer of VEGF sandwiched between two layers of 
anti-VEGF. The results suggest that co-delivery of VEGF and anti-VEGF narrows the pro-angiogenic 
region, which is favorable because formation of functional vasculature entails precise control over the 
scope and location of the angiogenic region. Through sensitivity analysis, we discovered that  VEGF 
diffusivity in tissue is the most important factor in controlling the amount of VEGF delivered to tissue. 
This suggests that the efficacy and practicability of 3-layered drug delivery system can be optimized 
through modulating diffusivity. This project indicates that the co-regulatory drug delivery system is a 
viable clinical option and that future research is warranted.  
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2. Introduction 
Vascular diseases are leading causes of death in America. Typically, heart attacks occur when 
plaque detaches from blood vessels and severely limits blood flow to vital organs. Even a partially clotted 
cardio vasculature can enervate oxygen transport and cause uncomfortable chest pain for the patient. To 
combat vascular diseases, it is imperative to understand the mechanism of vascular vessel formation in 
mammals, a process known as angiogenesis. During angiogenesis, blood vessels can sprout and split off 
from pre-existing vasculatures to create a myriad of patterns in order to provide tissues with sufficient 
nutrients
1. As shown in previous studies, angiogenesis is directed and regulated by growth factors, such as 
vascular endothelial growth factor (VEGF)
2, that target endothelial cells in the lining of blood vessels. In 
the absence of VEGF, endothelial cells will form leaky blood vessels that are unable to sustain constant 
blood flow
1.  
As previously mentioned, growth factors modify blood vessel formation. In particular, VEGF and 
its  inhibitor,  anti-VEGF,  accomplish  this  by  influencing  angioblast  (stem  cell)  differentiation
1.  Anti-
VEGF is an anti-angiogenic drug, commonly known as Avastin® (Bevacizumab injection). Avastin binds 
to VEGF secreted by cancer cells and inactivates its function. Effectively, anti-VEGF modulates VEGF 
and  restricts  the  growth  of  blood  vessels that  are  supplying  nutrients to  cancer  tumors.  The  clinical 
benefits of these growth factors prompted tremendous interests in the biomedical field to deliver them in-
vivo.  
Previous studies had shown that drugs can be successfully delivered into the body using synthetic 
polymer known as poly (lactic-co-glycolic) (PLG) scaffold
3. PLG scaffold is an implantable, nontoxic, 
and non-immunogenic drug delivery vehicle capable of maintaining a sustained release of VEGF, or other 
molecules. The drugs of interest are encapsulated in microspheres within the PLG matrix and released 
through erosion of the scaffold and diffusion of drug from scaffold. PLG scaffold has a wide range of 
applications: Chen RR et al. used PLG scaffold to deliver platelet derived growth factors (PDGF) and 
VEGF to study drug release kinetics in mice; Sun Q et al. delivered VEGF using PLG scaffold to mouse 
ischemic hind limbs and studied capillaries reformations; Rives CB et al. used two layered PLG scaffold 
to delivery plasmid DNA for in-vivo gene transfer. Although these findings indicated success with PLG 
delivery, there are drawbacks. The PLG drug release rate is initially very high, which can cause the 
buildup of drugs to toxic concentrations. In addition, PLG scaffold releases drugs mainly through the 
unregulated mode of diffusion, which may cause unwanted side effects on healthy tissues. One way to 
bypass these drawbacks, in relation to VEGF delivery, is to modulate the concentration of VEGF through 
anti-VEGF.  
The aim for this project is to develop an implantable vehicle for the co-delivery of VEGF and 
anti-VEGF. The method used will simultaneously deliver VEGF and anti-VEGF through PLG scaffold. In 
a typical implanted single layered PLG scaffold, the tissue containing diffused VEGF will be unregulated. 
As a result, the pro-angiogenic region caused by VEGF will be widespread and will lead to ineffective 
and incomplete vessel growth. This project attempts to address this problem by introducing anti-VEGF 
alongside with VEGF in a three-layered PLG scaffold. Anti-VEGF binds to VEGF and inhibits its uptake 
by endothelial cells. Effectively, anti-VEGF serves to modulate the concentration of free VEGF in the 
surrounding tissues that contain capillaries. This modulatory mechanism is important in establishing the 4 
 
targeted  region  of  angiogenesis.  More  specifically,  by  fine-tuning  the  region  affected  by  VEGF,  the 
proposed PLG delivery vehicle could induce angiogenesis with high spatial resolution. 
The result from this project can be used to justify the use of a three-layered scaffold to deliver 
inter-modulating  molecules.  In  particular,  the  inactivation  of  VEGF  by  anti-VEGF  may  provide  a 
spatially  and  temporally  controlled  angiogenic  promotion  region. This  result has  many  practical  and 
clinical  implications.  For example,  the  tri-layered  scaffold  can  precisely  target  the regeneration  of  a 
damaged capillary bed in vital organs. In addition, the growth of tumor vasculature may be stunted by the 
target  delivery  of  anti-VEGF  to  carcinogenic  regions  without  disrupting  healthy  tissues.  Lastly,  by 
regulating the initial burst release of VEGF by the PLG scaffold, the potential toxic effects of a high 
concentration of VEGF may be minimized.   
3. Design Objective 
Using COMSOL, we will model the concentration profile of VEGF and anti-VEGF in tissues 
surrounding the scaffold, along with the spatial and temporal interaction of VEGF and anti-VEGF by 
applying  binding  kinetics  and  degradation  reactions.  This  will  give  us  a  profile  of  effective  VEGF 
concentration in the area of interest.  
After obtaining the profile of free VEGF, we will modify various parameters in our model to 
gauge their effects on the VEGF profile. For example, we will vary the diffusivities of VEGF and anti-
VEGF and reaction rates to optimize our design. Specifically, we want to find the optimal parameters that 
allow the best spatial and temporal regulation of angiogenesis in the tissue surrounding the PLG scaffold.  
In summary, we have four design goals: 
i)  Design the optimal PLG scaffold to maintain a minimal effective concentration of free VEGF 
surrounding the tissue over time.  
ii)  Determine how diffusivities, reaction rates, and degradation rates affect the concentration of 
effective VEGF in the tissue. 
iii)  Model  the  interaction  between  VEGF  and  anti-VEGF  over  time,  by  modeling  protein 
degradation and complexation to each other.  
iv)  Spatially restrict the effective VEGF concentration to a narrow region next to the scaffold 
(allowed for pin point application of the scaffold).   
   5 
 
3.1 Problem Schematic  
 
Figure 1: Problem schematic for scaffold with 3 layers and nearby tissue. Dimensions are in millimeters. Insert figure shows 3D 
schematic of the proposed 3-layered scaffold in-vivo. Shaded area represents the desired angiogenic promotion region by VEGF.  
4. Results and Discussion 
4.1. Data from COMSOL modeling 
Initially, we tried to model the process with a scaffold containing  an initial concentration of 
VEGF and anti-VEGF. After we ran tests, however, results suggested that our goal of maintaining an 
effective interstitial concentration of VEGF could not be achieved with such design. With the old model, 
the drugs were not encapsulated in the PLG scaffold, which caused these molecules to freely diffuse out 
of the scaffold at a high initial flux. Subsequently, this caused majority of VEGF to be released from the 
scaffold and degraded in the tissue within a time period of one day (data not shown). Since our goal was 
to model a sustained release drug delivery vehicle for up to one week, we modified the model to make the 
PLG  scaffold  degradable.  Through  internal  degradation  (volume  remains  constant),  VEGF  and  anti-
VEGF molecules entrapped in the PLG polymer were slowly released into tissue over time, which was a 
more realistic representation of the actual physical process.  In summary, this method utilized a drug 
release rate instead of a simple diffusion from a uniformly concentrated scaffold.  
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4.1.1 Diffusion of VEGF and its modulator anti-VEGF   
With this method, we ran our model in COMSOL for a solution time of 1 week (604800 sec) with 
a  time  interval  of  one  hour.  COMSOL  solved  for  concentration  of  VEGF  (c1),  anti-VEGF(c2),  and 
complex (c3). The resulting concentration profiles are shown below (Figures 2, 5, 6). 
 
Figure 2: Surface plot of VEGF concentration after 7 days. The VEGF concentration was confined to a small region as desired in 
the objective.  
Although there were certain regions in the tissue domain with negative VEGF concentrations, 
these unphysical values were likely to be minor mesh density errors. One solution is to increase the 
number of mesh elements at the tissue region. However, since the computer has limited memory, we only 
increased mesh density and obtained convergence  in the region of interest: the area in and near the 
scaffold, where the most changes in the drug concentrations occurred.  Nonetheless, since the magnitudes 
of negative VEGF concentration  in the tissue area were  one order of magnitude lower, they can be 
considered negligible. The maximum VEGF concentration was 2.683 x 10
-5 mol/m
3 in the middle of the 
scaffold. In the tissue, the VEGF was confined to a small, narrow region just outside the middle scaffold 
layer, as desired (Figure 2). To determine the effect of anti-VEGF on VEGF distribution, the surface plot 
for the VEGF concentration in the absence of anti-VEGF was also generated (Figure 3). 
   
Figure 3: Surface plot of VEGF concentration after 7 days without anti-VEGF interaction. A finer mesh in the tissue region 
would decrease the area of negative concentrations. 7 
 
When analyzing the effect of anti-VEGF, the differences in VEGF distribution in the tissue were 
immediately striking. The concentration of VEGF in the tissue was modulated by anti-VEGF released 
from the top and bottom layers of the scaffold. Thus, the surface plot with anti-VEGF showed free-VEGF 
concentrated only near the middle layer-tissue interface (Figure 2), while the surface plot without VEGF 
showed free-VEGF concentrated along a wider range of the scaffold-tissue interface (Figure 3). This data 
suggests that our inter-modulating model was successful in spatially regulating VEGF concentration. 
Since the goal of this study was to localize an effective concentration of free-VEGF released from the 
scaffold, the free-VEGF concentration was further plotted against location and time (Figure 4). These 
plots show the spread of a therapeutic amount of free-VEGF as a function of times along the scaffold-
tissue interface. Figure 4A considers the VEGF spread without anti-VEGF, while figure 4B shows the 
inter-modulating effect of VEGF and anti-VEGF. Locations with a therapeutic concentration of VEGF 
will lead to angiogenic promotion as desired.  
 
                                          (A)                                                                                (B) 
Figure 4: Regions containing the therapeutic VEGF concentration of 0.5μg/mL along the scaffold-tissue boundary (r = 0.002 m) 
in the (A) absence or (B) presence of anti-VEGF. A value of 1 is assigned if this therapeutic value was met, while a value of 0 is 
assigned to insufficient VEGF concentrations. The x axes represent the distance from the top of the scaffold boundary, with the 
middle layer represented from 1 x 10
-3 m  to 2 x 10
-3 m. 
In the model without anti-VEGF delivery, the tissue contained a therapeutic VEGF concentration 
(c =  0.5µg/mL)  at the  scaffold-tissue  boundary  for most  z  values (Figure  4A). The  region  of tissue 
containing therapeutic VEGF concentration regressed as time increased to four days, but became more 
widespread again by seven days. This variable VEGF concentration can be attributed to the fast initial 
release of VEGF from the PLG scaffold. After 2 days, the initial burst release of VEGF decreased to a 
lower rate, which caused the regression of the angiogenic promotion region. The VEGF continued to 
accumulate till day seven, which presumably led to the increase of angiogenic promotion region.   
In  the  model  containing  anti-VEGF  delivery,  the  tissue  also  contained  a  therapeutic  VEGF 
concentration at the scaffold-tissue boundary for a relatively wide range of z values after day one (Figure 
4B). These levels of sufficient concentration became less prevalent as time progressed to day four. At all 
subsequent times, the VEGF was concentrated near the middle layer (1mm < z < 2mm). Over time, 
VEGF complexed with anti-VEGF, thus causing the angiogenic promotion region to become restricted 8 
 
over a narrower region. Therefore, the sustained effectiveness of anti-VEGF in spatially regulating the 
VEGF distribution can be confirmed. 
4.1.2. Diffusion of anti-VEGF and complex 
 
Figure 5: Surface plot of anti-VEGF concentration after 7 days. The anti-VEGF scarcely diffused into the tissue, since its 
diffusivity was much lower than that of the VEGF. 
The maximum anti-VEGF concentration of 6.205x10
-3 mol/m
3 occurred in the middle of the top 
scaffold layer (Figure 5). This observation makes sense because in the bottom scaffold layer, anti-VEGF 
is able to diffuse out both laterally and vertically through the side and bottom of the layer. On the other 
hand, in the top scaffold layer, anti-VEGF can only diffuse through the side since the top boundary is 
insulated. Thus, more anti-VEGF will remain in the top scaffold layer. Compared to the VEGF, the anti-
VEGF did not travel as far, due to its lower diffusivity. 
 
Figure 6: Surface plot of complex concentration after 7 days. The concentration of complex was located mainly around the 
scaffold-tissue interface at scaffold layer boundaries. 9 
 
The  maximum  complex  concentration  of  5.223  x 10
-3  mol/m
3  occurred  at the  scaffold-tissue 
boundary between adjacent layers (Figure 6). These regions were where the most VEGF could interact 
and complex with anti-VEGF molecules.  
4.1.3. Variation of VEGF, anti-VEGF, and complex concentrations over time 
Cross-sectional plots were produced at three different regions (Figure 7).   
 
Figure 7: Schematic of the domain of interest. Points represent regions of cross-sectional plots. 
 
Figure 8: VEGF concentration at the center of the middle layer over time in seconds. (Region 1: r=0.001, z=0.0015) 
There was an initial burst of VEGF concentration due to the higher initial release rate, resulting in 
concentrations of VEGF as high as 1.7 x 10
-4 mol/m
3 at region (1). The concentration then decreased, and 
continued to decrease as the release rate decreased after two days. Finally, the concentration reached 
steady  state  at  around  0.25  x  10
-4  mol/m
3,  a  desirable  condition  because  it  is  above  therapeutic 
concentration (Figure 8).  
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Figure 9: Concentration of VEGF-anti-VEGF complex at bottom corner of middle layer (r = 0.002 m, z = 0.001m) (A: Region 2) 
and at location right outside of the middle layer (r=0.002 m, z=0.0015 m) (B: Region 3) over time in seconds.  
At region (3), the concentration of the complex continually increased, as expected, because the 
VEGF diffused out to interact with anti-VEGF and form the complex (Figure 9B). On the other hand, 
region  (2)  had  a  higher  maximum  complex  concentration  because  there  were  more  free  anti-VEGF 
molecules at that location to bind with VEGF (Figure 9A). Also, a decrease in complex concentration 
after day one was consistent with the decrease of VEGF around t = 1.2 x 10
5 sec.  
 
Figure 10: Concentration of anti-VEGF at region (2) over time in seconds 
The  concentration  of  anti-VEGF  increased  with  time,  which  was  expected  because  these 
molecules were being continuously released from the scaffold. After one week, it reached a concentration 
of over 2.5 x 10
-3 mol/m
3 at region (2) (Figure 10). 11 
 
Additional  plots  of  VEGF  and  anti-VEGF  concentrations  against  the  boundary  of  the  scaffold  (z 
direction) for days (1, 2, 4, and 7) were generated (Figure 11). 
 
                                      (A)                                                                              (B) 
Figure 11: (A) VEGF and (B) anti-VEGF concentration at the scaffold/tissue interface as a function of z and time. 
For  all  times,  VEGF  was  concentrated  at  the  middle  scaffold  layer  boundary.  Initially, 
concentration of VEGF in this region was very high (Figure 11A). Later, however, VEGF diffused to 
surrounding tissue and interacted with anti-VEGF, causing these locally high concentrations to decrease 
over time from a maximum of 1.3 x10
-4 mol/m
3 after 1 day to less than 2 x 10
-5 mol/m
3 after a week. On 
the other hand, anti-VEGF was concentrated in the regions surrounding the top and bottom layer of the 
scaffold (Figure 11B). As time passed, the anti-VEGF concentrations increased rather than decreased 
when compared to VEGF concentration. Since anti-VEGF had a higher release rate than VEGF, more 
anti-VEGF was released than was diffusing and interacting with VEGF. Therefore, these concentrations 
increased with time from about 2.6 x 10
-3 mol/m
3 after a day to approximately 5.25 x 10
-3 mol/m
3 after a 
week. Furthermore, the anti-VEGF concentration was higher in the tissue near the bottom scaffold layer, 
since anti-VEGF molecules were able to more readily diffuse out of the side and bottom of this layer 
(Figure 5).  
 
Figure 12: Complex concentrations at the scaffold/tissue boundary at r = 0.002 m, as a function of z and time.  12 
 
The maximum concentration of complex occurred between the interface of VEGF and anti-VEGF 
scaffold layers at z=0.001m and z=0.002m (Figure 12). However, these maximums were initially closer to 
the anti-VEGF layers, later moving closer to the middle VEGF layer.  At first, anti-VEGF cannot diffuse 
far, and complex can only be formed when VEGF that has diffused quickly interacts with anti-VEGF near 
the top and bottom scaffold layers. Later, however, the anti-VEGF is able to diffuse more in the z-
direction. This will cause the maximum complex concentrations to occur closer to the VEGF source 
(Figure 12). Other VEGF, anti-VEGF, and complex concentration plots were made at different r-values 
(Figure 20, 21, 22). These plots can be found in the appendix. 
4.1.4. Penetration depth of VEGF into the tissue 
Figure 13: Effective VEGF concentration along the red line shown in the surface plot for different times, with the scaffold-tissue 
boundary represented by r = 0 m. The red dashed line represents the therapeutic concentration of 0.5 µg/mL. 
VEGF reached the therapeutic value one mm into the tissue after one day and approximately 0.2 
mm into the tissue after one week. While the penetration depth was only one millimeter after one day, this 
value kept decreasing, to approximately 0.2 mm after one week. This penetration depth is sufficient to 
provide angiogenic signals for 20 capillaries (8µm diameter) in a localized area. Thus, there would be 
sustained growth of blood vessels within 0.2 mm of the scaffold-tissue boundary, while there would still 
be some growth between 0.2 mm and 1 mm (Figure 13). In order to increase the penetration depth, which 
would allow growth of vasculature further deep into the tissue, some improvements can be made to the 13 
 
design. Increasing the initial loading concentration or release rate of VEGF would allow more VEGF to 
be released into the tissue and increase the penetration depth. Another approach is to add moieties to 
VEGF molecules that work to  slow down degradation of VEGF or inhibit the degradative enzymes, 
allowing VEGF to penetrate deeper into the tissue without being degraded. 
4.2 Sensitivity Analysis 
Variable parameters were changed by +/- 10%, as true values should not deviate greatly from 
those found in literature. The resulting VEGF concentration immediately outside of the middle scaffold 
was  measured,  since  this  area  is  where  the  greatest  concentration  gradients  occur  throughout  the 
computational domain and hence shows the effects of varying parameters most vividly. These changed 
values  were  normalized  against  the  original  values so  that  the  variations  could  be  compared  among 
different parameters (Figure 14). 
 
Figure 14: Sensitivity Analysis for diffusivities of VEGF and anti-VEGF in the PLG and tissue, the release rates from the 
scaffold and the degradation rates for both molecules, and complex reaction rates.  
Based on the sensitivity analysis, most parameters do not significantly affect the concentration of 
VEGF just outside the middle scaffold after 7 days. When the parameters were reduced by 10%, all 
parameters except the degradation rate for VEGF were within 10% of the original answer. Furthermore, 
changes in the release rates for both molecules did not affect the final answer at all. When the parameters 
were increased by 10%, all parameters except the diffusivity of VEGF in tissue resulted in solutions that 
changed less than 10% from the original answer. The diffusivities in PLG and release rates from scaffold 
did not affect the final answer when increased by 10% (Figure 14). Further detailed sensitivity analysis 
over time is presented in the appendix (Figure 23).  
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4.3. Validation (Accuracy Check) 
The simulation results show that our model made physiological sense. When the model was run 
without anti-VEGF (Figure 3), the VEGF diffused further and stayed at a higher concentration after a 
week compared to when the model was run in the presence of anti-VEGF (Figure 2). Anti-VEGF did not 
diffuse far from the scaffold compared to VEGF (Figure 5), which is reasonable because its diffusivity is 
over two orders of magnitude lower than that of VEGF. Finally, the complex surface plot showed the 
complex forming mainly near the outside of the scaffold at the layer boundaries (Figure 6). This result 
also made sense because this is the region where most VEGF intersected with anti-VEGF, leading to a 
high rate of local complexation. 
  The  plots  of  concentrations  over  time  further  validate  our  model.  At  region  (1),  VEGF 
concentration increased rapidly with the first initially high release rate. This concentration later decreased 
as the molecules had time to diffuse out of the scaffold and continued to decrease when the release rate 
was lowered at later times (Figure 8). In region (2), the anti-VEGF concentration increased continuously 
due to diffusion, while the rate of change decreased with time due to complexing (Figure 10). Region (2) 
also showed a complex concentration that initially bursted and then decayed, which was consistent with 
the  VEGF  concentration  profile.  Conversely,  region  (3)  showed  a  continuously  increasing  complex 
concentration (Figure 9). Since region (3) represented a location with a greater overlap of VEGF and anti-
VEGF, these plots also made sense. 
  Unfortunately,  an  analytical  solution,  which  is  a  great  source  of  validation  method,  is  not 
available and is too complex for the duration of this project. Another method to validate our model is to 
compare  the  results  computed  by  the  COMSOL  software  with  published  experimental  data.  Still, 
experimental data that exactly corresponds to our given process is not readily available; otherwise, there 
would be no need for computer simulation to solve this problem. With experimental data related to our 
model, we can compare the two sets of values at least on a cursory degree. 
A study explores the effectiveness of thermoresponsive hydrogel as a drug delivery agent. In this 
experiment, the authors encapsulated BSA (bovine serumalbumin) and immunoglobulin (IgG) into porous 
hydrogels made by cross-linking PNIPAAm (poly(N-isopropylacrylamide)) and PEG-DA (poly(ethylene 
glycol)), and then studied the release profiles of the encapsulated proteins from the hydrogel. 
The results show that there is initially a burst release of proteins for the first 48 hours and then a 
steady-state release rate afterwards (Figure 15).   15 
 
 
Figure 15: Release profile of immunoglobulin from hydrogel determined by experimentation by Kang DJ and Mieler WF 
[7]  
If we compare this experimentally determined release profile of IgG to our COMSOL-simulated 
anti-VEGF release profile, there is a similar trend with an initial burst release and an approximately 
steady-state release at later time point (Figure 16). The accuracy of our modeling is thus partly verified by 
the experimental values from a related situation. Our model suggests there is a burst release up to the first 
2000 minutes, whereas in the experiment this burst occurred up to about 1000 minutes. The difference can 
be attributed to different properties of thermoresponsive hydrogel and PLG. Also, the immunoglobulin 
used in the experiment can have different properties from Bevacizumab, the commercial anti-VEGF we 
used for modeling. What is important is that there was similarity in general release behaviors of the 
proteins in the experiment and the model.   
 
Figure 16: Release profile of anti-VEGF modeled by COMSOL over seven days. The percentage of anti-VEGF concentration 
released was plotted against time using concentration values at r = 0.002m, z = 0.0025m, the midpoint of the top layer of 
scaffold. 
  One of our major unphysical results was the appearance of negative concentrations. These values 
were due to a relatively coarse mesh in the tissue area. However, the mesh in tissue was not improved 
since the computer has a limited memory and the solution would not have changed in the area of interest, 
as  shown  in  the  mesh  convergence  analysis.  Furthermore,  the  magnitude  of  negative  values  was 
negligible compared to the true solutions. While this error could have been solved with the use of a finer 
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mesh, such a fix was not necessary to successfully model the region of interest—the tissue near the 
middle layer of the scaffold where most drug concentration gradient occurs. 
5. Conclusions and Design Recommendations 
5.1 Design Recommendations 
  Based on the results of our modeling of VEGF and anti-VEGF co-delivery into human tissue, 
several parameters have been determined to be important factors in designing the implantation device. 
Our design recommendations are thus built upon these issues with the aim to maximize the benefit of our 
treatment.   
1.  Use VEGF with controllable diffusivity in tissue to enable modulation of the amount of VEGF 
delivered: Decreased VEGF diffusivity in tissue causes VEGF molecules in areas immediately 
surrounding  the  scaffold  to  increase.  If  a  higher  concentration  of  VEGF  is  desired  near  the 
scaffold for more intensive angiogenesis, the manufacturer can decrease VEGF diffusivity by 
adding non-functional bulky groups to the VEGF molecules. 
2.  Use bio-degradable material to encapsulate the drugs, like the PLG used in modeling, because our 
results suggest that there should be frequent injections of the vehicle if the desired total duration 
of implantation lasts significantly longer than 7 days. Surgically replacing the implant each time 
will be costly and inconvenient. 
3.  Initial loading concentrations and release rates can be varied depending on the desired amount of 
VEGF delivered into tissue and the desired penetration depth. In order to increase the penetration 
depth,  use  higher  loading  concentrations  and  release  rates.  However,  increase  in  loading 
concentration should  be  carefully  monitored,  since a  drug  concentration that is too  high  can 
potentially be toxic to the tissue. To ensure a delivery of drug concentration that is therapeutically 
effectiveness but safe, the amounts of drugs used in our modeling can be used as reference values, 
since they have been shown to be within the safety and effectiveness limit (Effectiveness has 
been  proven  by  VEGF  amount  that  is  above  the  therapeutic  threshold  of  0.5  µg/mL  in  the 
simulation and safety can be confidently assumed because loading concentration values were 
taken from literature). 
5.2 Discussion on Realistic Constraints 
  Use  of  implantable  vehicle  for  co-delivering  VEGF  and  anti-VEGF  has  several  realistic 
constraints.  Further research  on  these  issues  will  have  to  be  conducted in  order  for  our implantable 
vehicle design to be put to practical use. 
  First, there are some health risks associated with using anti-VEGF antibodies as a neutralizing 
agent for VEGF molecules. A research has found that neutralizing VEGF with anti-VEGF can cause a 
dysfunction in kidney glomerulus and thereby proteinuria in cancer patients, which is a presence of excess 
serum proteins in urine. This condition is possibly caused by the ability of anti-VEGF to inhibit the power 
of VEGF to stimulate proper growth of glomerular endothelial cells, suggesting that excessive level of 
anti-VEGF in human bodies can cause such side-effects as kidney diseases.
[10] Balancing the amount of 
anti-VEGF appropriately with VEGF is therefore critical; although the amounts of drugs used in our 
modeling are considered safe, manufacturing real products should always be carried out with caution, 
keeping in mind that manufacturing defects can lead to critical clinical failures. 17 
 
  In addition, the health risk associated with administering this vehicle to certain groups of people 
has to be carefully examined before use. Our vehicle model is designed to stimulate angiogenesis in 
targeted areas of human bodies and therefore works as one of wound-healing methods. However, the 
presence of VEGF can be dangerous for cancer patients for whom VEGF can work as a trigger for the 
growth  of  tumor  by  inducing  abnormal  development  of  blood  vessels  and  delivering  oxygen  to  the 
malignant cancer cells. Therefore, the applicability of our vehicle is limited, especially for certain groups 
of patients such as cancer patients, where our vehicle can do more damage than repair.
[10] 
  Another type of constraint faced by this implant device is the economic implications. Our model 
suggests that the delivery of VEGF lasts for at least seven days, but whether it can last longer is at 
question due to the limited power of modeling. However, even in reality, injections of anti-VEGF in 
clinical practice are known to last only up to four to six weeks, necessitating multiple and repetitive 
intravitreal injections
 [8]. This increases both inconvenience and cost for patients in need of a prolonged 
angiogenic  treatment.  The  cost  of  anti-VEGF  drugs  vary,  and  among  the  three  most  common  anti-
VEGF’s (Macugen, Lucentis, Avastin), Avastin, the drug we used to model our vehicle is the least costly, 
but it is also the only one not FDA-approved at this point and used as ―off-label,‖ its long-term effects yet 
to be determined.
[9] The costliness of using our vehicle can constrain its availability to wide populations 
and  especially  to  economically  disadvantaged  groups.  Unequal  distribution  of  this  treatment  method 
across different socioeconomic groups can potentially cause social discomforts. In addition, the costliness 
of the vehicle also implies that affordability of this treatment can be an issue in developing countries, 
possibly limiting the extent of global marketing of this device.  
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Appendix A: Mathematical Statement of Problem 
 
Figure 17: Problem schematic for scaffold with 3 layers. Dimensions are in millimeters.  
Governing Equations 
In the PLG scaffold: 
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Where  i = 1: VEGF, i = 2: anti-VEGF, i = 3: VEGF-anti-VEGF complex 
ci = concentration of substance i 19 
 
Di,PLG = diffusivity of substance i in the PLG scaffold 
Di,tissue = diffusivity of substance i in the tissue 
di = degradation rate of substance i 
  kon = binding rate between VEGF and anti-VEGF 
  koff = disassociation rate of VEGF-anti-VEGF complex 
  kri = release rate of i 
  ciniti = initial loading concentration of i 
Boundary Conditions 
At the left boundary, there is symmetry so the fluxes of all species are zero. 
   
  
                              
The right boundary is far away, so the fluxes for all species are zero. 
   
  
                              
At the top boundary, there is insulation, so the fluxes for all species are zero. 
   
  
                              
The bottom boundary is far away, so the fluxes for all species are zero. 
   
  
                              
Initial Conditions  
The concentration of VEGF, anti-VEGF, and complex are zero in both scaffold and tissue. 
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Input Parameters 
Table 1: Constants used in COMSOL model. 
Diffusivities  Expression from Citation  Expression  Units  Sources 
VEGF  in Tissue  7.27E-07  cm
2/s  7.27E-11  m
2/s  [1] 
   in PLG  Dv_tissue*10  cm
2/s  7.27E-10  m
2/s    
anti-
VEGF  in Tissue  3.90E-09  cm
2/s  3.90E-13  m
2/s  [2] 
   in PLG  Da_tissue*10  cm
2/s  3.90E-12  m
2/s    
complex  in Tissue  3.90E-09  cm
2/s  3.90E-13  m
2/s  *Assumption 
Degradation Rate                
VEGF 
 
2.31E-04  s
-1 
 
   [1] 
anti-
VEGF 
 
7.04E-07  s
-1 
 
   [3] 
Volume of Scaffold                
  
 
      1.26E-08  m
3  Calculated 
Complexing Rate                
k_on (forward)  3.50E+04  M
-1s
-1  35  (mol/m
3*s)
-1  [4] 
k_off (backward)  6.30E-05  s
-1  6.3*10^-5  s
-1  [4] 
Release Rate in PLG 
(s
-1)   t<2days 
2days < t < 
7days  7days < t       
VEGF     2.30E-06  4.70E-07  2.30E-08  s
-1  [1] 
anti-
VEGF     2.88E-06  5.33E-07  2.88E-08  s
-1  Calculated 
 
Note: The diffusivities of VEGF, anti-VEGF in the PLG are assumed to be 10 times that of the diffusivities in the tissue. This is 
reasonable because the PLG scaffold is microporous. Therefore, there is less resistance to flow within the scaffold than in the 
tissue. 
 
Table 2: Expressions used in COMSOL model  
Rv_tiss  -dgrd_v*c-
k_on*c*c2+k_off*c3 
Degradation, complexed, dissociation for VEGF 
Ra_tiss  -dgrd_a*c2-
k_on*c*c2+k_off*c3 
Degradation, complexed, dissociation for anti-VEGF 
Rc_tiss  k_on*c*c2-k_off*c3  Degradation, complexed, dissociation for complex 
 
 
Appendix B: Solution Strategy  
 
To analyze the diffusion of VEGF, anti-VEGF, and the complex of VEGF bound to anti-VEGF, 
COMSOL Multiphysics was used to solve a transient diffusion problem with reaction. 
  
Solver: The direct (UMFPACK) solver was used to solve the algebraic equations.  
 
Time Stepping: Our model was run for 7 days. The time step used was 1 hour.  
 
Tolerance: The relative tolerance was 0.01 and the absolute tolerance was 0.0010.  21 
 
 
Mesh: We used a free mesh that placed more mesh elements in the 3-layer scaffold. The maximum 
element size and method for each subdomain is shown in Table 3. The mesh yielded was fine and had a 
shorter computation time compared to other meshes that have been tried. The resulting mesh is shown in 
Figure 18.  
 
Table 3: Free Mesh Parameters.  
Subdomain  Maximum Element Size  Method 
1. Tissue  1x10
-4  triangle (advancing front) 
2. Scaffold: anti-VEGF  2x10
-5  triangle (advancing front) 
3. Scaffold: VEGF  2x10
-5  triangle (advancing front) 
4. Scaffold: anti-VEGF  2x10
-5  triangle (advancing front) 
 
 
Figure 18: Meshing of computational domain in COMSOL. Comsol domain is 2D axial symmetric. The three left rectangles (2, 
3, 4) represent the different layers of the PLG scaffold. The large rectangular region (1) represents tissue. The mesh is finer at the 
scaffold  because  greater  changes  of  VEGF/anti-VEGF  concentrations  are  expected  at  that  region.  It  contains  48185  mesh 
elements. 
Mesh Convergence Analysis 
Mesh convergence analysis was completed for subdomains by varying maximum element size in 
subdomains 2,3,4, which represent the bottom, middle, and top layer of the PLG scaffold, respectively, 
since these are where the most mass transfers occur. Maximum element size stayed constant at 1.00 e-4 
for domain 1, which is the tissue region. Total amount of VEGF (in moles) left in the middle layer after 7 
days  of  simulation  was  used  as  the  indicator  for  convergence.  Post-processing  using  Subdomain 
Integration yielded the result that the point of convergence is at total mesh number of 48185 (Green circle 
in Figure 19). Different maximum element sizes were tried before arriving at our final mesh (Figure 18).  
1 
2 
3 
4 22 
 
 
Figure 19: Maximum element size was varied in subdomains 2,3,4. Maximum element size stayed constant at 1.00 x 10
-4 for 
subdomain. Plot of VEGF (in moles) in subdomain 3 after 7 days vs. total number of mesh elements. Point of convergence is at 
total mesh number of 48185 (Green circle). 
Table 4: Mesh Convergence Data 
  max. element 
size 
total 
element 
number 
total VEGF in 
PLG[mol] 
coarse  1.00E-04  9846  2.40E-13 
  8.00E-05  11132  2.41E-13 
  7.00E-05  11848  2.35E-13 
  6.00E-05  13012  2.68E-13 
  5.00E-05  14906  2.70E-13 
  4.00E-05  18662  2.62E-13 
  3.00E-05  26749  2.69E-13 
  2.50E-05  34165  2.69E-13 
CONVERGENCE   2.00E-05  48185  2.76E-13 
  1.50E-05  82747  2.77E-13 
refined  1.00E-05  164784  2.78E-13 
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Appendix C: Additional Visuals 
 
   
      (A)               (B) 
 
(C) 
Figure 20: (A) VEGF concentration in the tissue, close to the scaffold/tissue interface as a function of z and time at r=0.00225m. 
(B) VEGF concentration in the tissue as a  function of z and time at r=0.0035m. (C) Schematic  with red line representing 
r=0.00225m.  
During every time point, VEGF concentration was highest near the middle PLG layer. Initially, 
concentrations of VEGF in this region were very high. Later, however, VEGF diffuses to surrounding 
tissue and interacts with anti-VEGF, causing these locally high concentrations to decrease over time from 
a  maximum  of  3.65x10
-5  mol/m
3  after  1  day  to  0.5  x  10
-5  mol/m
3  after  a  week  (A).  The  initial 
concentration decreased from a maximum of about 3.3x10
-6 mol/m
3 after 1 day to 0.75 x 10
-6 mol/m
3 after 
7 days (B) (Figure 20). 
 24 
 
 
              (A)                  (B) 
Figure  21:  (A)  Anti-VEGF  concentrations  in  the  tissue  near  the  scaffold/tissue  boundary  as  a  function  of  z  and  time  at 
r=0.00225m. (B) Anti-VEGF concentration in tissue as function of z and t at r=0.0035m. 
Anti-VEGF was concentrated in the regions surrounding the top and bottom layer of the scaffold. 
As time passed, however, the anti-VEGF concentrations increased rather than decreased. With a higher 
release rate than with VEGF, more anti-VEGF is released than is diffusing and interacting with VEGF. 
Therefore, these concentrations increased with time after a week. Furthermore, the concentrations were 
higher near the bottom scaffold, as anti-VEGF is able to diffuse out through both the side and bottom of 
this layer. As r increases, the differences in anti-VEGF concentrations become less pronounced. This 
could be due to low diffusivity of anti-VEGF in tissue (Figure 21). 
 
         (A)                   (B) 
Figure 22: (A) Complex concentrations in the tissue near the scaffold/tissue boundary as a function of z and time at r=0.00225m. 
(B) Complex concentration in tissue as function of z and t at r=0.0035m. 25 
 
The maximum concentration of complex occurs between the interface of VEGF and anti-VEGF 
scaffold layers at r=0.001 and r=0.002. Once again, the maximums are initially closer to the anti-VEGF 
layers, later moving closer to the middle VEGF layer. This demonstrates that as time passes the anti-
VEGF is able to diffuse more in the z-direction. This will cause the maximum complex concentrations to 
occur closer to the source of VEGF release. As with the anti-VEGF plots, the differences in concentration 
in the z-direction are less pronounced at higher r values (Figure 22). 
Table 5: Variables tested for sensitivity analysis with the values used in our model.  
 
Variable  -10%  value used  10% 
Diffusivity VEGF in tissue (m
2/s)  6.54E-11  7.27E-11  8.00E-11 
Diffusivity anti-VEGF in tissue (m
2/s)  3.51E-13  3.90E-13  4.29E-13 
Diffusivity VEGF in PLG (m
2/s)  6.54E-10  7.27E-10  8.00E-10 
Diffusivity anti-VEGF in PLG (m
2/s)  3.51E-12  3.90E-12  4.29E-12 
Release rate VEGF (s
-1)  2.07E-08  2.30E-08  2.53E-08 
Release rate anti-VEGF (s
-1)  2.59E-08  2.88E-08  3.17E-08 
Degradation rate VEGF(s
-1)  2.08E-04  2.31E-04  2.54E-04 
Degradation rate anti-VEGF (s
-1)  6.34E-07  7.04E-07  7.74E-07 
Complexing rate ON ((mol/m
3*s)
-1)  3.15E01  3.50E01  3.85E01 
Complexing rate OFF (s
-1)  5.67E-05  6.30E-05  6.93E-05 
 
Sensitivity Analysis over time 
Degradations 
\  
                              (A)                                                            (B) 26 
 
Release Rates from Scaffold 
 
                                 (C)                                                                             (D) 
VEGF-anti-VEGF Complexing and Dissociation Rate 
 
(E)                                                                              (F) 
Diffusivity in PLG 
 
                                 (G)                                                                                        (H) 27 
 
Diffusivity in Tissue 
 
                                 (I)                                                                                        (J) 
Figure 23: Sensitivity analysis of major parameters in the PLG scaffold model. Each parameter was increased or decreased by 
10% and its effect on VEGF concentration immediately outside of the scaffold (middle layer [r: 0.002, z: 0.0015]) was plotted 
against time of (0s to 604800s [7days]) (A-J).  
From the concentration of VEGF over time solutions, it is clear that changes in almost all of the 
parameters have no significant effect on the final answer. The degradation rate and diffusivity of VEGF in 
the tissue have a visible effect on the solution at early times, but these differences decay at later times, as 
the VEGF concentration begins to reach steady state (Figure 23). Sensitivity analysis after full 7 days 
were already analyzed (Figure 14). 
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